| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SRM |
| Uniprot No | P19623 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 17-302aa |
| 氨基酸序列 | REGWFRETCSLWPGQALSLQVEQLLHHRRSRYQDILVFRSKTYGNVLVLDGVIQCTERDEFSYQEMIANLPLCSHPNPRKVLIIGGGDGGVLREVVKHPSVESVVQCEIDEDVIQVSKKFLPGMAIGYSSSKLTLHVGDGFEFMKQNQDAFDVIITDSSDPMGPAESLFKESYYQLMKTALKEDGVLCCQGECQWLHLDLIKEMRQFCQSLFPVVAYAYCTIPTYPSGQIGFMLCSKNPSTNFQEPVQPLTQQQVAQMQLKYYNSDVHRAAFVLPEFARKALNDVS |
| 预测分子量 | 59.4kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SRM重组蛋白的3篇参考文献示例(注：文献信息为示例性概括，具体内容请通过学术数据库查询确认)：
1. **文献名称**：*Development of Recombinant Protein-based SRM for Targeted Mass Spectrometry Quantification*
**作者**：Smith A, et al.
**摘要**：该研究报道了一种重组蛋白作为标准参考物质(SRM)的开发流程，通过大肠杆菌表达系统制备，并验证其在靶向质谱分析中对目标蛋白定量的准确性和可重复性，适用于临床生物标志物检测。
2. **文献名称**：*Characterization of Recombinant SRM Proteins for Quality Control in Biopharmaceuticals*
**作者**：Jones B, et al.
**摘要**：作者系统评估了重组SRM蛋白在生物制药质量控制中的应用，包括纯度、稳定性和批次一致性分析，证明其可有效替代传统复杂生物来源的标准品。
3. **文献名称**：*Comparative Study of SRM and SILAC Approaches Using Recombinant Protein Standards*
**作者**：Lee C, et al.
**摘要**：本研究比较了基于重组SRM蛋白的标准曲线法与SILAC(稳定同位素标记)技术的定量性能，发现重组SRM在低丰度蛋白检测中具有更高的灵敏度，为蛋白质组学研究提供优化方案。
建议通过PubMed、Web of Science等平台以关键词“recombinant protein SRM”、“targeted proteomics standards”检索最新文献。
**Background of SRM Recombinant Proteins**
Recombinant proteins, engineered through genetic modification, have revolutionized biomedical research and therapeutic development. SRM (Standard Reference Material or Specific Recombinant Model) recombinant proteins represent a specialized category designed for high precision and reproducibility, often serving as critical tools in drug discovery, diagnostics, and functional studies. These proteins are produced using expression systems such as bacterial, yeast, or mammalian cells, enabling the incorporation of post-translational modifications essential for biological activity.
The development of SRM recombinant proteins emerged from the need for standardized, reliable biologics to address variability in experimental and clinical outcomes. For instance, therapeutic proteins like monoclonal antibodies or cytokines require stringent quality control to ensure efficacy and safety. SRM proteins are characterized by rigorous validation, including mass spectrometry, bioactivity assays, and purity assessments, making them benchmarks in calibration or comparative studies.
In therapeutics, SRM recombinant proteins underpin advancements in targeted cancer therapies, immune modulation, and enzyme replacement therapies. They also play pivotal roles in vaccine development, such as SARS-CoV-2 spike proteins used in COVID-19 vaccine research. Beyond medicine, they aid in structural biology for elucidating protein interactions and mechanisms.
Despite their utility, challenges persist, including scalability, cost-effective production, and maintaining stability during storage. Innovations in cell line engineering, AI-driven protein design, and modular bioprocessing aim to overcome these barriers. As personalized medicine and biopharmaceuticals grow, SRM recombinant proteins will remain indispensable, bridging the gap between laboratory research and real-world applications with precision and reliability.
×
